EUS-RFA for Unresectable Pancreatic Ductal Adenocarcinoma
Endoscopic Ultrasound Guided Radiofrequency Ablation (EUS-RFA) for Unresectable Pancreatic Adenocarcinoma - a Randomised Controlled Trial
Sponsor: First People's Hospital of Hangzhou
A NA clinical study on Pancreatic Adenocarcinoma Non-resectable, this trial is completed. The trial is conducted by First People's Hospital of Hangzhou and has accumulated 7 data snapshots since 2018. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Sep 2021 — Jul 2024 [monthly]
Completed NA
Status: Recruiting → Completed
-
Jan 2021 — Sep 2021 [monthly]
Recruiting NA
-
Apr 2020 — Jan 2021 [monthly]
Recruiting NA
▶ Show 2 earlier versions
-
Feb 2019 — Apr 2020 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
-
Jan 2019 — Feb 2019 [monthly]
Not Yet Recruiting NA
First recorded
Dec 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- First People's Hospital of Hangzhou
For direct contact, visit the study record on ClinicalTrials.gov .